Showing results (51-60 of 65) with videos related to
Sort By:
Pageof 7
Bone Marrow Transplantation|November 5, 2022
Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT studyPeter Svec, Reem Elfeky, Jacques-Emmanuel Galimard, et al.Blood|July 5, 2024
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHDYu Akahoshi, Nikolaos Spyrou, Daniela Weber, et al.Transplantation and Cellular Therapy|September 27, 2025
Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease SeverityIoannis Evangelos Louloudis, Yi-Bin Chen, Nikolaos Spyrou, et al.Transplantation and Cellular Therapy|September 2, 2024
Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White PatientsCarlos A Ortega Rios, Muna Qayed, Aaron M Etra, et al.Blood|March 17, 2018
MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHDHannah Major-Monfried, Anne S Renteria, Attaphol Pawarode, et al.Bone Marrow Transplantation|August 26, 2025
A survey on the practices and the management of hemorrhagic cystitis in patients who undergo allogeneic hematopoietic stem cell transplantation, on behalf of the Infectious Diseases Working Party of EBMTSimone Cesaro, Inge Verheggen, Gloria Tridello, et al.Journal for Immunotherapy of Cancer|January 13, 2023
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammationViktoria Marquardt, Johanna Theruvath, David Pauck, et al.Blood Advances|February 7, 2024
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysisYu Akahoshi, Nikolaos Spyrou, Matthias Hoepting, et al.Blood Advances|April 19, 2024
Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHDAaron Etra, Najla El Jurdi, Nikolaos Katsivelos, et al.Blood Advances|June 14, 2023
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHDYu Akahoshi, Nikolaos Spyrou, William J Hogan, et al.Pageof 7